Skip To Main Content

Actualización normativa

En un entorno en constante cambio como el sistema de salud, es fundamental mantenerse al día con las nuevas normativas que afectan tanto a profesionales como a pacientes. En este espacio encontrará las leyes, decretos, resoluciones y acuerdos relacionados con el sistema de salud dinámico y en evolución.

También encontrará resúmenes, análisis y todo lo relacionado con la más reciente normatividad, para comprender el posible impacto de los cambios hacia los diferentes actores del sistema.

Ordenar por
What is Bullous Pemphigoid

What is Bullous Pemphigoid

The heterogeneous presentation of bullous pemphigoid may shed light on why patients are underdiagnosed. Read the article to learn more

Patient morbidity and mortality in BP

Patient morbidity and mortality in BP

Many factors, including older age and multimorbidity, are associated with mortality in bullous pemphigoid. Read this article to find out more

What is Bullous Pemphigoid

What is Bullous Pemphigoid

The heterogeneous presentation of bullous pemphigoid may shed light on why patients are underdiagnosed. Read the article to learn more

Treatments and challenges for bullous pemphigoid

Treatments and challenges for bullous pemphigoid

Systemic corticosteroids and other immunosuppressants are the current mainstay of therapy but carry risks for patients with bullous pemphigoid. Read this article to find out more

Pathophysiology of Bullous Pemphigoid

Pathophysiology of Bullous Pemphigoid

In bullous pemphigoid, autoimmunity to BP180 and BP230 is thought to trigger a type 2 inflammatory response. Read this article to find out more

Pathophysiology of Bullous Pemphigoid

Pathophysiology of Bullous Pemphigoid

In bullous pemphigoid, autoimmunity to BP180 and BP230 is thought to trigger a type 2 inflammatory response. Read this article to find out more

Considerations for bullous pemphigoid management

Considerations for bullous pemphigoid management

The management of bullous pemphigoid is challenging and new treatment approaches are needed. Read this article to find out more.

Pathophysiology of Bullous Pemphigoid

Pathophysiology of Bullous Pemphigoid

In bullous pemphigoid, autoimmunity to BP180 and BP230 is thought to trigger a type 2 inflammatory response. Read this article to find out more

Considerations for bullous pemphigoid management

Considerations for bullous pemphigoid management

The management of bullous pemphigoid is challenging and new treatment approaches are needed. Read this article to find out more.

Considerations for bullous pemphigoid management

Considerations for bullous pemphigoid management

The management of bullous pemphigoid is challenging and new treatment approaches are needed. Read this article to find out more.

Treatments and challenges for bullous pemphigoid

Treatments and challenges for bullous pemphigoid

Systemic corticosteroids and other immunosuppressants are the current mainstay of therapy but carry risks for patients with bullous pemphigoid. Read this article to find out more

Treatments and challenges for bullous pemphigoid

Treatments and challenges for bullous pemphigoid

Systemic corticosteroids and other immunosuppressants are the current mainstay of therapy but carry risks for patients with bullous pemphigoid. Read this article to find out more

Material diseñado por o para Sanofi Aventis de Colombia S.A., con fines educativos y dirigido a profesionales de la salud y personal administrativo del sector salud. Es estrictamente prohibido compartir este material con terceros.

Mayor información a disposición en el Departamento Médico:

En Colombia:

Sanofi-Aventis de Colombia S.A. Transversal 23 N° 97-73 - Edificio City Business. Piso 8. Bogotá D.C. Teléfono: 621 4400 - Fax: 744 4237

infomedica.colombia@sanofi.com

En Bolivia, Centro América y Caribe:

Sanofi-Aventis de Panamá S.A. Torre Evolution, piso 26, Calle 50 y Av. Aquilino de la Guardia Obarrio- Cuidad de Panamá, República de Panamá Telf.: (507) 382-9500. infomed.pac@sanofi.com

Sitio web: http://www.sanofi.com.pa/l/pa/sp/index.jsp

 

MAT-CO-2400825 V1.0 03/2024